ZG006
Phase 3Small molecule
ZG006 is one of 158 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
5
Indications
9
Total Trials
9
Active Trials
157
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Cabometyx
Bristol-Myers SquibbPhase 3
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Ritalin
NovartisPhase 3
Xaluritamig
AmgenPhase 3
ZG006
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Triptorelin Embonate
IpsenPhase 3
Fluciclovine
UUniversity of Utah
Phase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuroendocrine Carcinoma4 trials
Small Cell Lung Cancer2 trials
Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ZG006. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details